Eli Lilly announced positive Phase 2 results for eloralintide, a selective amylin receptor agonist, showing placebo-adjusted weight loss ranging from 9.1% to 19.7% over 48 weeks. The drug demonstrated a favorable tolerability profile and improvements in cardiometabolic markers. Based on these data, Lilly plans to initiate Phase 3 trials for obesity treatment next month.